Foghorn Therapeutics Inc (FHTX) - Total Assets
Based on the latest financial reports, Foghorn Therapeutics Inc (FHTX) holds total assets worth $203.39 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Foghorn Therapeutics Inc - Total Assets Trend (2018–2025)
This chart illustrates how Foghorn Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see FHTX market cap for the company's overall valuation and market capitalisation.
Foghorn Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Foghorn Therapeutics Inc's total assets of $203.39 Million consist of 82.4% current assets and 17.6% non-current assets. Review total liabilities of Foghorn Therapeutics Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 40.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Foghorn Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Foghorn Therapeutics Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Foghorn Therapeutics Inc's current assets represent 82.4% of total assets in 2025, a decrease from 93.8% in 2018.
- Cash Position: Cash and equivalents constituted 40.8% of total assets in 2025, down from 92.9% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Foghorn Therapeutics Inc Competitors by Total Assets
Key competitors of Foghorn Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Foghorn Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.36 | 2.62 | 6.42 |
| Quick Ratio | 3.36 | 2.62 | 6.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $119.47 Million | $126.06 Million | $104.66 Million |
Foghorn Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Foghorn Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2005.35 |
| Latest Market Cap to Assets Ratio | 1.26 |
| Asset Growth Rate (YoY) | -30.2% |
| Total Assets | $198.10 Million |
| Market Capitalization | $249.42 Million USD |
Valuation Analysis
Above Book Valuation: The market values Foghorn Therapeutics Inc's assets above their book value (1.26x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Foghorn Therapeutics Inc's assets decreased by 30.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Foghorn Therapeutics Inc (2018–2025)
The table below shows the annual total assets of Foghorn Therapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $198.10 Million | -30.24% |
| 2024-12-31 | $283.98 Million | -0.68% |
| 2023-12-31 | $285.92 Million | -29.38% |
| 2022-12-31 | $404.88 Million | -22.10% |
| 2021-12-31 | $519.77 Million | +103.36% |
| 2020-12-31 | $255.59 Million | +1044.01% |
| 2019-12-31 | $22.34 Million | -48.11% |
| 2018-12-31 | $43.06 Million | -- |
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mu… Read more